DNTH · Dianthus Therapeutics, Inc.

Current Thesis

Clinical-stage complement biotech built around a single asset, claseprubart (DNTH103) a selective anti-C1s mAb dosed Q2W subcutaneous, moving to Q4W in Phase 3. The setup the prior dossier was framing (pre-readout accumulation into an H2-2026 gMG topline) is obsolete: the MaGic Phase 2 gMG readout already happened on 2025-09-08 and was positive, and CIDP CAPTIVATE then delivered an early Phase 3 "GO" decision that re-rated the stock and pulled the entire sell-side up behind it. This is no longer a pre-binary trade it is a post-de-risking platform whose narrative leg has been fully monetized. Market cap is up ~630% YoY to $4.40B, the 52-week range is $16.64–$96.50, consensus PT sits at $121.17 (Strong Buy, 12 analysts), and a $719M raise at $81.00 closed 2026-03-12. The stock now sits at $80.51 (2026-06-05), consolidating directly on that offering shelf. The remaining edge is narrow and conditional: accumulate only on a clean hold of the $81 institutional cost basis, with the MMN MoMeNtum Phase 2 topline (2H-26) as the next live repricer. Chasing strength here is buying after the sell-side, the inverse of this book's edge. Still applies forward binaries (MMN, Phase 3 reads) remain but the fat-pitch accumulation window is closed.

Bull Case

• gMG MaGic Phase 2 positive (2025-09-08): both 300mg and 600mg Q2W hit statistically significant MG-ADL and QMG improvements, onset from week 1, sustained through week 13, with no serious infections, no autoimmune symptoms, no serious drug-related AEs. Management's "best-in-class profile" claim is supported by clean safety, not just efficacy.
• CIDP CAPTIVATE early GO: the Phase 3 reached its responder bar early 20 confirmed responders with fewer than 40 patients completing open-label Part A a genuine clinical de-risk on a second >$1B indication. This was the catalyst that drove the March 2026 upgrade cascade.
• Sell-side fully aligned: Raymond James upgraded to Strong Buy and lifted PT $63→$123 (2026-03-10); HC Wainwright moved PT $47→$130; Wells Fargo initiated Overweight (2026-03-19). Consensus PT $121.17 vs $80.51 spot implies ~50% upside if Phase 3 execution holds.
• Fortress balance sheet: $514.4M cash at 2025-12-31 plus ~$719M gross from the March raise = ~$1.1B+ pro forma, runway extended well past the prior "into 2028" guide. No financing overhang into the next data set the dilution event already cleared at $81.
• Mechanism differentiation: selective classical-pathway C1s inhibition preserves alternative/lectin immunity, the credible infection-risk label edge vs eculizumab/ravulizumab (Soliris/Ultomiris) and UCB's zilucoplan (Zilbrysq). Q4W dosing in Phase 3 is a real convenience vector vs weekly/bi-weekly FcRn loading.
• Enrollment friction reduced: the FDA dropped antinuclear-antibody screening as a criterion across the claseprubart program (theoretical drug-induced-lupus concern resolved), a modest tailwind to trial throughput.

Bear Case

• The re-rate already happened: $16→$96 on the 52-week tape, market cap $4.40B, sell-side caught up. Buying now is buying after the narrative was published the opposite of catching it 1-3 weeks early. The probability-weighted DCF already prices substantial Phase 3 success.
• No near-term hard catalyst: the next data binary is MMN MoMeNtum (2H-26, no firm date); the Phase 3 gMG topline is 2H-28, years of holding risk away. Dead time between catalysts is pure opportunity cost in a momentum book.
• Single-molecule, single point of failure: one asset across gMG, CIDP and MMN. A negative MMN print or a CAPTIVATE Part B (randomized-withdrawal) failure that doesn't confirm the early-GO responder signal craters the platform optionality in one session.
• Insider distribution at the highs: EVP R&D Randhawa sold 26,530 shares at $89.17–$91.96 (~$2.4M) on 2026-06-01 under a 10b5-1 plan. Not a panic signal, but no insider is adding at $81 either;
• gMG competitive density stays brutal: argenx Vyvgart / Vyvgart-Hytrulo SC, UCB Zilbrysq, J&J nipocalimab (Imaavy, approved 2025), Alexion/AZN Ultomiris. Phase 3 must show separation, and that proof is 2H-28. Commercial entry is far out and a lot can break in between.
• Serial issuer: the March raise was upsized $625M→$719M with full greenshoe plus 402,468 pre-funded warrants. Balance sheet is strong now, but the pattern is repeat ATM/follow-on supply on strength.

Setup & Price Structure

• Spot $80.51 (2026-06-05 close), −4.3% on the day, intraday range $79.64–$85.82, volume ~836K.
• 52-week range $16.64–$96.50 currently ~16% off the high after the post-raise fade. Market cap $4.40B (+629.9% YoY). Beta 0.07: this is an idiosyncratic, catalyst-driven name that does not track XBI or index beta day-to-day, so sector sympathy bids are weak it grinds on company news.
• The $81.00 offering price (2026-03-12) is the structural line. It is the institutional cost basis from the $719M raise and now acts as the pivot: a hold here builds a consolidation base; a decisive loss on volume signals distribution below where the marginal institutional buyer is underwater. Spot is sitting fractionally below it ($80.51), so this is the test in real time.
• No precise 20/50/200-DMA stack was piped this session, but the relevant frame is binary: defend $81 → base; lose $81 on >1.5x volume → air toward gap-fill, given how vertically the stock ran from the teens.
• Theme status: MATURING. The narrative accelerated, the sell-side fully caught up (12 analysts, Strong Buy, $121 PT), and the stock is now consolidating, not trending. New upside requires a fresh catalyst, not continuation.

Catalyst Calendar (next 30 days)

• Phase 3 gMG initiation guided mid-2026 (~June–July 2026, est.). Process milestone, not a data print; modest repricing power but confirms program momentum.
• CIDP CAPTIVATE Part B / further interim data interim responder analysis was guided to Q2-26 (~by 2026-06-30, est.); the early-GO largely consumed it, so any incremental disclosure is confirmatory rather than binary.
• No PDUFA / FDA action date no approved asset yet.
• Out of window (flagged for context): MMN MoMeNtum Phase 2 topline ~2H-26 (next true binary); Q2-26 earnings ~early August 2026; Phase 3 gMG topline 2H-28.
• Net: no hard 10–50% data binary inside the next 30 days. The honest read is a catalyst gap, which argues for patience on the $81 shelf over a chase.

What Would Change Our Mind

• Bull-confirming: a clean weekly hold and reclaim above $81–$85 on rising volume into a dated MMN MoMeNtum readout window would re-establish an accumulation base worth sizing.
• Bear-confirming / thesis-break: a weekly close below the $81.00 offering shelf on >1.5x average volume (institutional floor lost); a negative or merely non-differentiated MMN MoMeNtum topline (2H-26); CAPTIVATE Part B failing to confirm the early-GO responder signal; or a fresh ATM/follow-on announced into weakness rather than strength.
• Re-rating risk: a competitor gMG/CIDP print (argenx, UCB, J&J) landing with clearly superior separation would lift the Phase 3 bar claseprubart must clear in 2H-28 before the company ever reads out, compressing the multiple ahead of data.

Correlation Notes

• Low index/sector correlation (beta 0.07) DNTH moves on its own catalyst clock, not the XBI tape, so it is a poor expression of a broad biotech-beta view and a clean expression of company-specific de-risking.
• Mechanism-basket peers (argenx ARGX, UCB, Immunovant IMVT, J&J nipocalimab franchise) drive the competitive bar in gMG/CIDP; a strong competitor readout is a relative-value headwind even when DNTH-specific news is quiet.
• Rate-sensitive, pre-revenue duration asset: in a risk-off, rising-rate tape, long-dated clinical biotech compresses regardless of pipeline quality the $1.1B+ cash cushion mutes financing risk but not multiple risk.
• Theme cohort: rare-disease-approvals / complement-biotech / autoimmune-neuromuscular. The cohort already had its sell-side catch-up cycle; further theme-level upside likely requires a new positive print from a basket member rather than continuation of the existing bid.